Investigating how TET2 affects leukemia in the bone marrow environment
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
This study is looking at how a specific enzyme called TET2 affects acute myeloid leukemia (AML) in patients with TET2 mutations, to find new ways to treat those who aren't responding to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10932998 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the TET2 enzyme in acute myeloid leukemia (AML), particularly in patients with TET2 mutations or deletions. It aims to explore how TET2 deficiency influences the behavior of leukemia stem cells within the bone marrow microenvironment, which is crucial for their survival and growth. By studying the molecular mechanisms involved, the research seeks to identify new therapeutic targets and develop innovative treatment strategies for AML patients who are currently unresponsive to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with TET2 mutations or deletions.
Not a fit: Patients with acute myeloid leukemia who do not have TET2 mutations or deletions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with TET2-deficient acute myeloid leukemia, improving their outcomes.
How similar studies have performed: While the specific approach of targeting TET2 in the leukemia microenvironment is novel, there is emerging evidence supporting the importance of similar molecular mechanisms in other cancer studies.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Chen, Jianjun — Beckman Research Institute/city of Hope
- Study coordinator: Chen, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.